Global AttentionDeficit Hyperactivity Disorder (ADHD) Therapeutics Market, by Drug Type(Stimulants (Amphetamine, Methylphenidate, Dextroamphetamine,Dexmethylphenidate, and Lisdexamfetamine Dimesylate) and Non-stimulants(Atomoxetine, Bupropion, Guanfacine, and Clonidine), by Age Group (Pediatricand Adolescent, and Adult), by Distribution Channel (Specialty Clinics,Hospital Pharmacies, Retail Pharmacies, and E-commerce), and by Region (NorthAmerica, Latin America, Europe, Asia Pacific, Middle East, and Africa), isestimated to be valued at US$ 18,169.0 million in 2020 and is expected to exhibit a CAGR of 7.1 % during theforecast period (2020-2027), as highlighted in a new report published byCoherent Market Insights.
Key companies are focusing onrising approval of new products from the regulatory authority, in order toprovide better options for treatment of ADHD in pediatric and adolescentpatients, which is expected to bolster market growth over the forecast period.For instance, in August 2018, Ironshore Pharmaceuticals & Development,Inc., a subsidiary of Highland Therapeutics Inc., received the U.S. Food andDrug Administration (FDA) approval for its New Drug Application (NDA) forJORNAY PM (methylphenidate) for the treatment of attention deficithyperactivity disorder (ADHD) in patients aged 6 years and older.
Global Attention DeficitHyperactivity Disorder (ADHD) Therapeutics Market – Impact of Coronavirus(COVID-19)
The COVID-19 pandemic hasdrastically impacted each and every market across the world. Therefore,government of various countries are taking initiatives to combatattention-deficit hyperactivity disorder (ADHD) amid Covid-19.
* The sample copy includes: Report Summary, Table ofContents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copyof this report: https://www.coherentmarketinsights.com/insight/request-sample/830
In order to manage attention deficithyperactivity disorder (ADHD) during the COVID-19 pandemic, organizations suchas National Resource Center on ADHD (NRC), Children and Adults withAttention-Deficit/ Hyperactivity Disorder (CHADD), and others provide educationand support, and spread awareness about attention deficit hyperactivitydisorder among the patients suffering from ADHD. Such organizations are fundedby government organizations including the Centers for Disease Control andPrevention (CDC). For instance, on July 1, 2020, the Center for Disease Controland Prevention (CDC) highlighted the negative effects of social distancing.They reported that social distancing increased mental stress among the peopleand it is more evident in ADHD patients, due to which the behavioral problemsin some of the ADHD patients have become worse.
Browse 35 Market Data Tables and38 Figures spread through 181 Pages and in-depth TOC on “Global AttentionDeficit Hyperactivity Disorder (ADHD) Therapeutics Market, by Drug Type(Stimulants (Amphetamine, Methylphenidate, Dextroamphetamine,Dexmethylphenidate, and Lisdexamfetamine Dimesylate) and Non-stimulants(Atomoxetine, Bupropion, Guanfacine, and Clonidine), by Age Group (Pediatricand Adolescent, and Adult), by Distribution Channel (Specialty Clinics,Hospital Pharmacies, Retail Pharmacies, and E-commerce), and by Region (NorthAmerica, Latin America, Europe, Asia Pacific, Middle East, and Africa)”
The market is expected to witnesssignificant growth during the forecast period, owing to key players focusing onlaunch of new ADHD services and formation of new hubs for the diagnosis,assessment, and treatment of ADHD. For instance, in September 2020,Nottinghamshire Healthcare announced the launch of attention deficithyperactivity disorder (ADHD) service, wherein adults with ADHD inNottinghamshire can receive the support for diagnostic assessment and the righttreatment.
Browse ResearchReport: https://www.coherentmarketinsights.com/market-insight/attention-deficit-hyperactivity-disorder-treatment-market-830
Key Takeaways of the GlobalAttention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market:
The global attention deficithyperactivity disorder (ADHD) therapeutics market is expected to exhibit a CAGRof 7.1% during the forecast period, owing to key companies focusing on productlaunches and approval for the treatment of attention deficit hyperactivitydisorder (ADHD)
Among drug type, stimulantssegment is expected to hold major market share in the global attention deficithyperactivity disorder (ADHD) therapeutics market during the forecast period,owing to an increasing number of launch of new products for the treatment ofpatients with ADHD by key companies
Among age group, adults segmentis expected to hold major market share in the global attention deficithyperactivity disorder (ADHD) therapeutics market during the forecast period,owing to increasing prevalence of attention deficit hyperactivity disorder(ADHD) in adult population globally
Among distribution channel,retail pharmacies segment is expected to hold major market share in the globalattention deficit hyperactivity disorder (ADHD) therapeutics market during theforecast period, owing to increasing number of retail pharmacies & chainstores, easy access of products, and strategic tie-ups between major companies& retail pharmacies
Key players operating in theglobal attention deficit hyperactivity disorder (ADHD) therapeutics marketinclude Amneal Pharmaceuticals, Inc., Eli Lilly And Company, JanssenPharmaceuticals, Inc., Noven Pharmaceuticals, Inc., RespireRx PharmaceuticalsInc., Otsuka Pharmaceutical Co., Ltd, Neos Therapeutics, Inc., American Brivision(Holding) Corporation, Novartis International AG, Takeda Pharmaceutical CompanyLimited, GlaxoSmithKline plc., and Purdue Pharma L.P.
Buy-Now this researchreport: https://www.coherentmarketinsights.com/insight/buy-now/830
AboutCoherent Market Insights:
CoherentMarket Insights is a prominent market research and consulting firm offeringaction-ready syndicated research reports, custom market analysis, consultingservices, and competitive analysis through various recommendations related toemerging market trends, technologies, and potential absolute dollaropportunity.
ContactUs:
mailto:sales@coherentmarketinsights.com
U.S.Office:
Name: Mr. Shah
CoherentMarket Insights 1001 4th Ave,
# 3200Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN: +050-5539-1737
